The grant of a patent is not an automatic entitlement that follows from novelty or inventive step alone. Before any invention can be examined on those standard criteria, it must first clear a foundational threshold: it must constitute a patentable subject matter under Indian law. The Patents Act, 1970 draws this threshold with deliberate precision in Section 3, which enumerates categories of subject matter that shall not be regarded as inventions for the purposes of the Act. Section 3 is not a peripheral provision. It is one of the most frequently invoked and hotly contested portions of Indian patent law and its correct understanding is indispensable for any applicant, practitioner or institution seeking to navigate the Indian patent system.
The provision reflects a deliberate legislative philosophy: that patents are granted in exchange for genuine technical contribution to the stock of human knowledge and that certain categories of subject matter – whether because they are abstract, contrary to public interest, naturally occurring or insufficiently inventive – do not justify the grant of a statutory monopoly. India’s approach under Section 3 is shaped by its domestic policy priorities particularly in the pharmaceutical and technology sectors and by its obligations under the Agreement on Trade-Related Aspects of Intellectual Property Rights. Where the TRIPS Agreement permits member states to define exclusions from patentability on grounds of public order, morality and certain specific subject matters, India has exercised those flexibilities with considerable legislative intent. Each sub-clause of Section 3 encodes a policy judgment and understanding that judgment is as important as knowing the text of the provision itself.
Section 3(a) – Frivolous Inventions and Claims Contrary to Natural Laws
Section 3(a) excludes from patentability an invention that is frivolous or that claims anything obviously contrary to well-established natural laws. This is the most elementary of the exclusions and its application is correspondingly rare in formal examination proceedings, though it sets an important baseline. A claim to a perpetual motion machine one that purports to generate energy without any input is the canonical example of a claim obviously contrary to natural laws and would be rejected under Section 3(a) without further analysis. The word “frivolous” captures inventions that are so trivial in nature or so manifestly impractical that granting them a patent would represent an abuse of the patent system. In practice, Section 3(a) functions as a safeguard against bad-faith or speculative filings but does not generate significant jurisprudence because its application is relatively straightforward.
Section 3(b) – Public Order, Morality and the Prevention of Serious Prejudice
Section 3(b) excludes inventions that’s primary or intended use or commercial exploitation, would be contrary to public order or morality or which cause serious prejudice to human, animal or plant life, health or to the environment. This provision operationalise one of the core TRIPS flexibilities Article 27.2 of TRIPS expressly permits member states to exclude from patentability inventions whose commercial exploitation would be contrary to ordre public or morality, provided that such exclusion is not made merely because exploitation is prohibited by domestic law.
The scope of Section 3(b) is necessarily interpretive. It does not exclude all inventions that carry risk – virtually every pharmaceutical, chemical or industrial invention has some potential for harm. What it targets is inventions whose very purpose or primary use is harmful or whose exploitation would create serious environmental or health prejudice without redemptive utility. The exclusion has particular relevance in the context of dual-use technologies, certain biotechnological inventions and inventions whose claimed applications raise ethical concerns. It should be noted that the mere fact that an invention is prohibited from sale or use under another Indian statute does not, by itself, trigger Section 3(b) the question is whether commercial exploitation of the invention is contrary to public order or morality in a meaningful sense, not merely whether some regulatory bar exists.
Section 3(c) – Discoveries of Naturally Occurring Substances
Section 3(c) provides that the mere discovery of a scientific principle or the formulation of an abstract theory or discovery of any living thing or non-living substance occurring in nature shall not be regarded as an invention. This exclusion is foundational to the distinction between discovery and invention that underpins the entire patent system. A patent is granted for an invention for the creation or application of something new by human ingenuity. It is not granted for the identification or isolation of what already exists in the natural world.
The word “mere” carries significant weight in Section 3(c). A naturally occurring substance that has been identified and isolated in pure form is not patentable as a discovery. However, a new process for extracting or synthesizing that substance or a novel formulation that enhances its utility in a specific application, may constitute a patentable invention if it satisfies the standard criteria. This distinction between the substance itself and the inventive process or application relating to it is central to biotechnology and pharmaceutical patent practice in India and it intersects closely with Section 3(d) in the context of naturally occurring biological molecules.
Section 3(d) – Incremental Modifications and the Anti-Evergreening Provision
No provision of Section 3 has attracted as much domestic and international attention as Section 3(d) and none has been as consequential for India’s position in global intellectual property debates. Section 3(d) provides that the mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance shall not be regarded as an invention. It further provides, by way of Explanation, that salts, esters, ethers, polymorphs, metabolites, pure forms, particle sizes, isomers, mixtures of isomers, complexes, combinations and other derivatives of known substances shall be considered to be the same substance unless they differ significantly in properties with regard to efficacy.
The purpose of Section 3(d) is to prevent pharmaceutical Evergreening – the practice by which patent holders seek to extend the effective period of patent protection over a drug by patenting incremental modifications such as new salt forms, polymorphs or esters of the active compound, without demonstrating that these modifications produce meaningfully better therapeutic outcomes. India inserted Section 3(d) into the Patents Act through the 2005 amendment precisely because it was aware, in acceding to TRIPS product patent protection for pharmaceuticals, that without such a provision, the pharmaceutical patent landscape could become dominated by Evergreening strategies that delay generic entry and inflate drug prices without delivering genuine innovation to patients.
The Supreme Court of India provided the definitive interpretation of Section 3(d) in Novartis AG v. Union of India, (2013) 6 SCC 1. Novartis sought a patent for the beta-crystalline form of Imatinib Mesylate, the active ingredient in Gleevec, a drug used to treat chronic myeloid leukaemia. The Patent Office rejected the application under Section 3(d), a decision that was upheld through the appellate hierarchy and ultimately confirmed by the Supreme Court. The Court held that the beta-crystalline form was a new form of a known substance – Imatinib and that Novartis had failed to demonstrate that it resulted in a significant enhancement of the known efficacy of Imatinib. The Court further held that the word “efficacy” in Section 3(d), in the context of a pharmaceutical substance, means therapeutic efficacy – the ability of the substance to produce the intended pharmacological effect in a patient and that improved bio availability alone does not constitute enhanced efficacy unless it can be shown to translate into enhanced therapeutic effect. This interpretation set a demanding standard and confirmed India’s right to calibrate its patentability thresholds in a manner responsive to public health imperatives.
Section 3(e) – Aggregations and Mixtures without Synergy
Section 3(e) excludes from patentability a substance obtained by a mere admixture resulting only in the aggregation of properties of the components thereof or a process for producing such a substance. The rationale is straightforward: the simple combination of known substances, where the resulting mixture does nothing more than display the individual properties of each component, involves no inventive contribution. The combination is not greater than the sum of its parts. For a mixture to be patentable, the combination must produce a synergistic effect – an outcome that is qualitatively different from and cannot be predicted from, the mere addition of the individual properties of the components.
This provision has significant implications for formulation patents in the pharmaceutical and chemical industries. A combination drug that merely delivers two known active ingredients together, without any unexpected pharmacological interaction or enhanced therapeutic effect arising from the combination, is vulnerable to objection under Section 3(e). By contrast, a fixed-dose combination that demonstrates a synergistic therapeutic effect where the combined action of the two compounds exceeds what would be expected from their individual administration – may constitute a genuine invention not caught by this exclusion.
Section 3(f) – Rearrangement of Known Devices
Section 3(f) excludes the mere arrangement or rearrangement or duplication of known devices, each functioning independently of one another in a known way. This exclusion targets mechanical or structural combinations where the constituent components simply perform their known functions without producing any new or unexpected result from their combination. The provision distinguishes between a genuine combination invention where the interaction of components produces a novel technical result and a collocation of devices that remain individually functional and produce no collective technical contribution beyond the sum of their separate functions.
Section 3(g) – Methods of Agriculture and Horticulture
Section 3(g) provides that a method of agriculture or horticulture shall not be regarded as an invention. This exclusion reflects a policy judgment that agricultural practices including cultivation methods, crop rotation techniques and horticultural processes should remain freely available to farmers and the agricultural community and should not be capable of being monopolized through patent grants. The exclusion is consistent with India’s status as a predominantly agrarian economy with a constitutional commitment to the welfare of the farming community. It should be noted that Section 3(g) excludes methods of agriculture and horticulture, not agricultural products or biotechnological inventions more broadly the latter are addressed through other provisions, including Section 3(j).
Section 3(h) – Methods of Treatment
Section 3(h) excludes any process for the medicinal, surgical, curative, prophylactic, diagnostic, therapeutic or other treatment of human beings or any process for a similar treatment of animals or plants to render them free of disease or to increase their economic value. This exclusion ensures that methods by which medical practitioners treat patients remain freely available to the medical profession and cannot be subject to patent monopoly. The policy rationale is compelling: allowing patents on methods of treatment would create a situation in which doctors could be liable for patent infringement in the course of treating their patients an outcome that would fundamentally compromise the delivery of healthcare.
The exclusion under Section 3(h) applies to processes, not to the substances or devices used in those processes. A pharmaceutical compound used in treatment is patentable subject to the standard criteria and the requirements of Section 3(d). A medical device used in surgery is similarly patentable in principle. What cannot be patented is the method of treatment itself the clinical procedure by which a drug is administered, a surgical operation is performed or a diagnostic process is applied to a patient.
Section 3(i) – Plant Varieties and Animal Breeds
Section 3(i) provides that plants and animals in whole or any part thereof other than microorganisms but including seeds, varieties and species and essentially biological processes for production or propagation of plants and animals shall not be regarded as inventions. This exclusion reflects India’s position, consistent with Article 27.3(b) of TRIPS that plant varieties and animal breeds as such are not patentable under the Patents Act and that protection for plant varieties should be provided through the dedicated sui generis framework established by the Protection of Plant Varieties and Farmers’ Rights Act, 2001.
The carve-out for microorganisms is significant. While plants, animals and essentially biological processes are excluded, micro-organisms per se and microbiological processes including processes for producing substances using micro-organisms may be patentable where they involve human technical intervention and are not merely naturally occurring. This distinction has important implications for biotechnology patent practice, particularly in the pharmaceutical, fermentation and industrial biochemistry sectors.
Section 3(j) – Mathematical Methods, Business Methods, Algorithms and Computer Programmes per Se
Section 3(j) – numbered as Section 3(k) in the current version of the Act following legislative renumbering – excludes mathematical methods, business methods, computer programmes per se and algorithms. The rationale for excluding mathematical methods and algorithms is that abstract intellectual constructs formulae, logical procedures and computational rules are discoveries of conceptual relationships, not technical inventions. Granting a patent over a mathematical method would, in effect, monopolize a domain of abstract knowledge and remove it from the public domain of ideas, in a manner that would impede rather than promote innovation.
The exclusion of business methods reflects the legislative view that commercial strategies, financial schemes and organizational processes do not constitute the kind of technical contribution to human knowledge that patent protection is intended to reward. The most consequential aspect of this provision, however – and the one that has generated by far the most examination practice and litigation is the exclusion of computer programmes per se. As discussed in the context of AI and software patents, the qualifier “per se” preserves patentability for computer-implemented inventions that produce a technical effect beyond the mere execution of a programme. An invention that deploys software as a means to achieve a concrete technical result in a physical system, a technical process or a defined application domain may cross the threshold, even though the software in isolation would not.
Section 3(k) – Aesthetic Creations and Literary or Artistic Works
Section 3(k) – renumbered in practice – excludes aesthetic creations including works of art, literature, music, dramatic works and other aesthetic productions. These are protected, where applicable, under the Copyright Act, 1957, which provides a distinct and more appropriate form of protection for creative and artistic expression. The intellectual property system distinguishes sharply between functional and technical creations the domain of patents and creative and aesthetic expressions the domain of copyright. Section 3(k) gives statutory expression to this distinction within the patent framework.
Section 3(l) – Mental Acts, Games and Rules
This provision excludes a mere scheme or rule or method of performing mental act or method of playing game. The exclusion of mental acts follows from the same logic that underlies the exclusion of mathematical methods and abstract theories: a method that is performed purely in the mind, without any physical or technical implementation, does not constitute a technical invention. Rules for playing games whether traditional board games or modern digital games similarly represent organizational or creative constructs rather than technical contributions to the patent system.
Section 3(m) – Presentation of Information
The presentation of information however novel the format or medium is not patentable subject matter. The content of a presentation, the data it conveys or the organizational scheme it employs do not constitute technical inventions. This exclusion must, however, be carefully distinguished from inventions directed to the technical means by which information is processed, stored or transmitted, which may be patentable where they produce a genuine technical result independent of the informational content itself.
Section 3(n) – Topography of Integrated Circuits
Section 3(n) provides that topography of integrated circuits shall not be regarded as an invention under the Patents Act. Layout designs of integrated circuits are governed by a dedicated framework the Semiconductor Integrated Circuits Layout-Design Act, 2000 which provides sui generis protection tailored to the specific characteristics of semiconductor chip designs. The exclusion from patent protection ensures that the two regimes do not overlap and that the specialized framework for layout-design protection operates without interference from the patent system.
Section 3(o) – Traditional Knowledge and Aggregated Traditional Knowledge
Section 3(o) excludes inventions that in effect are traditional knowledge or which are an aggregation or duplication of known properties of traditionally known component or components. This provision addresses a critical concern for India the risk that traditional knowledge held collectively by communities, codified in ancient texts or practiced for centuries in agriculture, medicine and crafts, could be appropriated through patent grants to private parties who have done nothing more than document, rediscover or superficially reformulate that knowledge.
India has invested significantly in the creation of the Traditional Knowledge Digital Library – a structured, searchable database of traditional knowledge drawn from Ayurveda, Unani, Siddha and Yoga texts precisely to create prior art that can be cited against patent applications seeking to appropriate traditional knowledge through the patent system. Section 3(o) provides the statutory foundation for this effort, making explicit that the aggregation or duplication of known properties of traditional components, without genuine inventive contribution, is not patentable subject matter. This provision has been invoked successfully to oppose and revoke patents granted in foreign jurisdictions including the celebrated cases involving turmeric, neem and Basmati rice and represents a significant dimension of India’s broader engagement with biopiracy concerns in international IP forums.
The Relationship between Section 3 and Standard Patentability Criteria
It is important to understand that Section 3 operates as a gateway distinct from the standard patentability criteria of novelty, inventive step and industrial applicability. An invention may be entirely novel, may involve a genuine inventive step and may have clear industrial applicability and still be excluded from patentability by Section 3. The exclusions in Section 3 are not redundant with the standard criteria. They address qualitatively different concerns: not whether an invention is new or obvious, but whether it belongs to a category of subject matter that should be open to patent protection at all. Examination practice in India requires examiners to assess Section 3 objections independently of and prior to, the assessment of novelty and inventive step. An applicant facing a Section 3 objection must address it directly, typically by demonstrating through specification, claims and argument that the invention does not fall within the excluded category or that, where the relevant provision contains a qualifying word such as “mere” or “per se,” the invention transcends the bare form of the excluded subject matter and makes a contribution of the required character.
Judicial and Administrative Interpretation – The Evolving Landscape
The interpretation of Section 3 has been progressively developed through decisions of the Controller of Patents, the Intellectual Property Appellate Board and the higher courts. The Supreme Court’s judgment in Novartis remains the most authoritative pronouncement on Section 3(d) and its therapeutic efficacy standard. The Delhi High Court’s engagement with Section 3(k) in the context of computer-implemented inventions and AI has brought Indian practice progressively closer to the technical effect framework of the European Patent Office. The Controller’s decisions in pharmaceutical cases including those involving combination drugs, polymorphs and biological molecules have built a body of administrative practice that, while not always consistent in its application, provides useful guidance on how each sub-clause of Section 3 operates in practice.
What emerges from this body of jurisprudence is a picture of Section 3 as a living framework one whose application is context-sensitive, fact-specific and responsive to the technological and policy context in which each application is filed. The exclusions in Section 3 are not mechanical rules but policy instruments and their application requires an understanding of the purpose each sub-clause serves and the kind of contribution – or absence of contribution that it is designed to address.
Conclusion
Section 3 of the Patents Act, 1970 is the most important gatekeeping provision in Indian patent law. It defines the outer boundary of what the Indian patent system will protect and, by implication, what it will leave in the public domain. Its provisions range from the self-evidently excluded perpetual motion machines, scientific discoveries to the intensely contested pharmaceutical polymorphs, computer-implemented inventions, traditional knowledge and each sub-clause encodes a distinct policy judgment about the proper scope of patent protection.
For applicants, understanding Section 3 is not merely a matter of identifying obstacles to be overcome. It is an exercise in understanding what kind of intellectual contribution the Indian patent system values, what it treats as a genuine technical invention and what it reserves as the common heritage of scientific knowledge, natural diversity and cultural tradition. An application drafted with a clear understanding of Section 3 one that frames the invention’s contribution precisely, anticipates likely exclusions and supports its claims with specification content that addresses the relevant sub-clauses is far more likely to succeed than one that treats Section 3 as an afterthought.
India’s approach under Section 3 has attracted both praise and criticism in international IP circles. It has been praised as a model of responsible patent policy that preserves access to medicines and protects traditional knowledge. It has been criticized by industry groups as creating uncertainty and excluding legitimate pharmaceutical innovation. Whatever one’s view of those debates, Section 3 is certain to remain at the center of Indian patent practice and its interpretation will continue to evolve as new technologies, new industries and new public interest challenges place fresh demands on a statutory framework drafted more than five decades ago.
References
- The Patents Act, 1970 – https://ipindia.gov.in
- Novartis AG v. Union of India, (2013) 6 SCC 1 – https://main.sci.gov.in
- Guidelines for Examination of Computer Related Inventions (CRI Guidelines), 2017 – https://ipindia.gov.in/writereaddata/Portal/IPOGuidelinesManuals/1_73_1_CRI_Guidelines_August_2015.pdf
- Manual of Patent Office Practice and Procedure – https://ipindia.gov.in
- Protection of Plant Varieties and Farmers’ Rights Act, 2001 – https://plantauthority.gov.in
- Semiconductor Integrated Circuits Layout-Design Act, 2000 – https://ipindia.gov.in
- Traditional Knowledge Digital Library – https://www.tkdl.res.in
- TRIPS Agreement, WTO – https://www.wto.org/english/docs_e/legal_e/27-trips.pdf
- National IPR Policy, 2016, DPIIT – https://dpiit.gov.in
- Bayer Corporation v. Natco Pharma Ltd., IPAB Order, 2013 – https://ipindia.gov.in
Copyright Act Copyright Act 1957 Copyright Infringement Copyright Law Copyright Rules Indian IP Framework Indian Patent Law Indian Trademark Law Intellectual Property Law IP Law India Patent Enforcement Patent Infringement Patent law Trademark Registration Trade Marks Act 1999 TRIPS Compliance